Получена: 25/05/2023/ Принята: 18/10/2023 / Опубликована online: 30/10/2023
УДК 61: 616-01/09-002- 616.61-002.1
DOI 10.53511/PHARMKAZ.2023.33.55.013
Д.М. ДЕМЕУБАЕВА1, Г.Ж. КАПАНОВА2, А.М. ГРЖИБОВСКИЙ3, С.А. ДИКАНБАЕВА4,Г.Т. ТАШЕНОВА5, Н.Е. ЖАППАРГАЛЫ6, З.А. ДАТХАЕВА7
1-2Казахский Национальный университет им.Аль-Фараби, г. Алматы, Казахстан
3Северо-Восточный федеральный университет им. М.К. Аммосова, Якутск, Россия
4Казахстанско-Российский медицинский университет, г. Алматы, Казахстан
5-6-7Казахский Национальный медицинский университет им. С.Д.Асфендиярова, Казахстан, г. Алматы
СОВРЕМЕННЫЙ ВЗГЛЯД И НОВЫЕ ПЕРСПЕКТИВЫ НЕФРОПРОТЕКТИВНОЙ
ТЕРАПИИ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК
Резюме: Хроническая болезнь почек – это термин объединяющий всех пациентов с сохраняющимися 3 и более месяцев признаками повреждения почек с или без нарушения их функций.
Доказано, что нефропротективная терапия позволяет снизить риск развития терминальной стадии ХБП до 50%. Несмотря на то, что разработаны и утверждены Протоколы диагностики и лечения ХБП, до настоящего времени выявление ранних стадий ХБП страдает. Как правило дети
поступают в отделения нефрологии в 4-5 стадии ХБП. В связи с этим, в настоящее время, особое
значение в профилактике прогрессирования ХБП имеет ее ранняя диагностика.
Статистические данные указывают на относительно низкие показатели смертности от ХБП. Это
вполне закономерно, если учесть темпы развития и совершенствования методов нефропротекции и
заместительной почечной терапии. Основной причиной смертности пациентов с ХБП является поражение сердечно-сосудистой системы. Доказано, что развитие ренального синдрома является фактором прогрессирования сердечно-сосудистых заболеваний. С другой стороны, исход ХБП находится в прямой зависимости от тяжести в степени прогрессирования кардиального синдрома. Этому
способствует гиперхолестеринемия, гиперурикемия, нарушение фосфорно-кальциевого обмена и анемия, протеинурия и другие факторы, объединяющие понятие нарушение метаболического обмена.
Основная цель этого оценочного обзора- идентификация и качественный синтез статей по нефропротективной терапии для предотвращения прогрессирования хронической болезни почек.
Материалы и методы. Исследование представляет собой оценочный обзор, доступных литературных данных. Поиск литературы проводился в базах PubMed, Scopus, Web of Science, Springer. Поисковые запросы и комбинации терминов проводились в PubMed, Scopus, Web of Science и Springer.
Дублирующие публикации были проверены и удалены. Первоначально было идентифицировано 315
статьи. После удаления дубликатов в результате поиска в электронных базах данных и просмотра ссылок на статьи, а также применение критериев включения / исключения и тщательное изучение рефератов привело к 15 статьям подходящих для качественного синтеза.
Результаты и обсуждение
Были представлены препараты, обладающие нефропротективным, антипротеинурическим, гипотензивным эффектами, их влияние на предотвращение дальнейшего снижения скорости клубочковой фильтрации. Проблема отсутствия эффективной терапии с минимизацией побочных эффектов в детской нефрологии, требует изучения возможностей применения новых медикаментозных
средств, нацеленных на нефропротекцию.
Ключевые слова: хроническая болезнь почек и нефропротективная терапия или заболевания почек и нефропротекция, взрослые и дети и скорость клубочковой фильтрации, прогрессирование.
СПИСОК ЛИТЕРАТУРЫ
1 K. C. Norris et al., “Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURECKD,” BMC Nephrol., vol. 20, no. 1, Nov. 2019, doi: 10.1186/S12882-019-1558-9.
2 S. K. Venuthurupalli, W. E. Hoy, H. G. Healy, A. Cameron, and R. G. Fassett, “CKD.QLD: establishment of a chronic kidney disease [CKD] registry in
Queensland, Australia,” BMC Nephrol., vol. 18, no. 1, Jun. 2017, doi: 10.1186/S12882-017-0607-5
3 Bikbov B., Purcell C.A., Levey A.S., Smith M., Abdoli A., Abebe M., Adebayo O.M., Afarideh M., Agarwal S.K., Agudelo-Botero M., et al. Global, regional,
and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the global burden of disease study 2017. Lancet. 2020;395:709–733.
doi: 10.1016/S0140-6736(20)30045-3
4 Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai CY, Floyd T, Al-Aly Z. Analysis of the global burden of disease study highlights the global,
regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567–581. doi: 10.1016/j.kint.2018.04.011
5 Rojas-Morales P, León-Contreras JC, Sánchez-Tapia M, Silva-Palacios A, Cano-Martínez A, González-Reyes S, Jiménez-Osorio AS, Hernández-Pando
R, Osorio-Alonso H, Sánchez-Lozada LG, Tovar AR, Pedraza-Chaverri J, Tapia E. A ketogenic diet attenuates acute and chronic ischemic kidney injury and
reduces markers ofoxidative stress and inflammation. Life Sci. 2022 Jan 15;289:120227. doi:10.1016/j.lfs.2021.120227. Epub 2021 Dec 16. PMID: 34921866
6 Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – a systematic review and metaanalysis. PLoS ONE. (2016) 11:e0158765. doi: 10.1371/journal.pone.0158765
7 Ren Q, Cheng L, Guo F, Tao S, Zhang C, Ma L, Fu P. Fisetin Improves Hyperuricemia-Induced Chronic Kidney Disease via Regulating Gut MicrobiotaMediated Tryptophan Metabolism and Aryl Hydrocarbon Receptor Activation. J Agric Food Chem. 2021 Sep 22;69(37):10932-10942. doi: 10.1021/acs.
jafc.1c03449. Epub 2021 Sep 10. PMID: 34505780.
8 E. J. Will, “A short cultural history of the UK Renal Registry 1995-2020,” BMC Nephrol., vol. 21, no. 1, Aug. 2020, doi: 10.1186/S12882-020-01997-1.
9 Piperidou A, Loutradis C, Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021 Jan;35(1):12-
25. doi: 10.1038/s41371-020-00393-4. Epub 2020 Aug 10. PMID: 32778748
10 Nowak N, Yamanouchi M, Satake E. The Nephroprotective Properties of Extracellular Vesicles in Experimental Models of Chronic Kidney Disease:
a Systematic Review. Stem Cell Rev Rep. 2022 Mar;18(3):902-932. doi:10.1007/s12015-021-10189-9. Epub 2021 Jun 10. PMID: 34110587; PMCID:
PMC8942930.
11 Podzolkov VI, Bragina AE. Chronic kidney disease as a multidisciplinary problem of contemporary medicine. Ter Arkh. 2018 Jun 20;90(6):121-129.
doi:10.26442/terarkh2018906121-129. PMID: 30701915
12 Sarafidis P, Papadopoulos CE, Kamperidis V, Giannakoulas G, Doumas M.Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors
and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved. Hypertension. 2021 May 5;77(5):1442-1455. doi: 10.1161/
HYPERTENSIONAHA.121.17005. Epub 2021 Mar 29. PMID: 33775130.
13 Smeijer JD, Koomen JV, Kohan DE, McMurray JJV, Bakris GL, Correa-Rotter R,Hou FF, Kitzman DW, Makino H, Mayer G, Nowicki M, Perkovic V, Rossing
P, Tobe S,Parving HH, de Zeeuw D, Heerspink HJL. Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response
to Atrasentan in Patients With Diabetic Kidney Disease. Clin Pharmacol Ther. 2022 Nov;112(5):1098-1107.doi: 10.1002/cpt.2721. Epub 2022 Aug 11. PMID:
35892316.
14 Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. 1: Alfano G, Perrone R, Fontana F, Ligabue G, Giovanella S, Ferrari
A, Gregorini M, Cappelli G, Magistroni R, Donati G. Rethinking Chronic Kidney Disease in the Aging Population. Life (Basel). 2022 Oct 28;12(11):1724.
doi:10.3390/life12111724. PMID: 36362879.
15 Bobkova IN, Moiseev SV, Lysenko LV, Kamyshova ES. [Lupus nephritis in the XXI century]. Ter Arkh. 2022 Aug 4;94(6):713-717. Russian. doi:10.26442
/00403660.2022.06.201559. PMID: 36286846.
16 Delanaye P, De Seigneux S. Finérénone : une nouvelle avancée sur le chemin de la néphroprotection [Finerenone: a new step on the way to
nephroprotection]. Rev Med Suisse. 2022 Aug 24;18(792):1534-1538. French. doi:10.53738/REVMED.2022.18.792.1534. PMID: 36004652
17 Capolongo G, Capasso G, Viggiano D. A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter
2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics. Int J Mol Sci. 2022 Apr 1;23(7):3915. doi: 10.3390/ijms23073915.
PMID: 35409276; PMCID: PMC8999762
18 Yao L, Zhao R, He S, Feng Q, Qiao Y, Wang P, Li J. Effects of salvianolic acid A and salvianolic acid B in renal interstitial fibrosis via PDGF-C/PDGFR-α
signaling pathway. Phytomedicine. 2022 Nov;106:154414. doi: 10.1016/j.phymed.2022.154414. Epub 2022 Aug 27. PMID: 36057144.
19 Miltonprabu S, Sumedha NC, Senthilraja P. Diallyl trisulfide, a garlic polysulfide protects against As-induced renal oxidative nephrotoxicity, apoptosis and
inflammation in rats by activating the Nrf2/ARE signaling pathway. Int Immunopharmacol. 2017 Sep;50:107-120. doi: 10.1016/j.intimp.2017.06.011. Epub 2017
Jun 23. Retraction in: Int Immunopharmacol. 2020 Aug;85:106621. PMID: 28648972.
20 Statistics committee Ministry of National Economy of the Republic of Kazakhstan . Main Socio-Economic Indicators. 2019
21 Organization WH . Noncommunicable Diseases (NCD) country profiles 2018: Kazakhstan. Geneva: World Health Organization; 2018.
22 Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K. Global and regional diabetes
prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract.
2019;157:107843. doi: 10.1016/j.diabres.2019.107843.
23 Piperidou A, Loutradis C, Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021
Jan;35(1):12-25. doi: 10.1038/s41371-020-00393-4. Epub 2020 Aug 10. PMID: 32778748
24 Carriazo S, Ortiz A. Stopping kidney protection in the elderly following acute kidney injury: think mortality. Clin Kidney J. 2022 Feb 2;15(6):1037-1040. doi:
10.1093/ckj/sfac024. PMID: 35664273; PMCID: PMC9155224.
25 Gautam G, Parveen B, Umar Khan M, Sharma I, Kumar Sharma A, Parveen R, Ahmad S. A systematic review on nephron protective AYUSH drugs as
constituents of NEERI-KFT (A traditional Indian polyherbal formulation) for the management of chronic kidney disease. Saudi J Biol Sci. 2021 Nov;28(11):6441-
6453. doi:10.1016/j.sjbs.2021.07.008. Epub 2021 Jul 12. PMID: 34764761; PMCID: PMC8568826.
26 Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020
May;16(5):269-288. doi: 10.1038/s41581-019-0248-y. Epub 2020 Feb 14. PMID: 32060481
27 Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017; 389(10075): 1238- 1252.
28 Packer M. Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes. J Diabetes Complications.
2020 Sep;34(9):107647. doi: 10.1016/j.jdiacomp.2020.107647. Epub 2020 Jun 5. PMID: 32534886.
29 Casanova AG, López-Hernández FJ, Vicente-Vicente L, Morales AI. Are Antioxidants Useful in Preventing the Progression of Chronic Kidney Disease?
Antioxidants (Basel). 2021 Oct 23;10(11):1669. doi: 10.3390/antiox10111669. PMID: 34829540; PMCID: PMC8614781.
30 4Mihai S, Codrici E, Popescu ID, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res.
2018; 2018: 1- 16.
31 3Fraser SDS, Roderick PJ. Kidney disease in the global burden of disease study 2017. Nat Rev Nephrol. 2019; 15(4): 193- 194.
32 Piperidou A, Loutradis C, Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021
Jan;35(1):12-25. doi: 10.1038/s41371-020-00393-4. Epub 2020 Aug 10. PMID: 32778748)
33 Fang CY, Lou DY, Zhou LQ, Wang JC, Yang B, He QJ, Wang JJ, Weng QJ. Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta
Pharmacol Sin. 2021 Dec;42(12):1951-1969. doi: 10.1038/s41401-021-00620-9. Epub 2021 Mar 9. Erratum in: Acta Pharmacol Sin. 2022 Oct 19;: PMID:
33750909; PMCID: PMC8633358.
34 Pontremoli R, Borghi C, Perrone Filardi P. Renal protection in chronic heart failure: focus on sacubitril/valsartan. Eur Heart J Cardiovasc Pharmacother.
2021 Sep 21;7(5):445-452. doi: 10.1093/ehjcvp/pvab030. PMID: 33822031; PMCID: PMC8453284.
35 Awuah Boadi E, Shin S, Bandyopadhyay BC. Tannic acid attenuates vascular calcification-induced proximal tubular cells damage through paracrine
signaling. Biomed Pharmacother. 2021 Aug;140:111762. doi: 10.1016/j.biopha.2021.111762. Epub 2021 Jun 12. PMID: 34126317; PMCID: PMC8753424.
36 R. Shah and M. A. Sparks, “Renin-angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go?,” Curr. Opin.
Nephrol. Hypertens., vol. 28, no. 2, pp. 171–177, Mar. 2019, doi: 10.1097/MNH.0000000000000484.
37 Zhang Y, Böckhaus J, Wang F, Wang S, Rubel D, Gross O, Ding J. Genotype- phenotype correlations and nephroprotective effects of RAAS inhibition
in patients with autosomal recessive Alport syndrome. Pediatr Nephrol. 2021 Sep;36(9):2719-2730. doi: 10.1007/s00467-021-05040-9. Epub 2021 Mar 27.
PMID: 33772369; PMCID: PMC8370956.
38 Tsukamoto S, Okami N, Yamada T, Azushima K, Yamaji T, Kinguchi S, Uneda K, Kanaoka T, Wakui H, Tamura K. Prevention of kidney function decline
using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clin Rheumatol. 2022 Mar;41(3):911-919.
doi: 10.1007/s10067-021-05956-5. Epub 2021 Oct 12. PMID: 34642880.
39 C. S. Park et al., “Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis
of data from the Korean acute myocardial infarction registry-national institutes of health registry,” Front. Cardiovasc. Med., vol. 9, Aug. 2022, doi: 10.3389/
FCVM.2022.994419.
40 K. H. Moore and J. S. Clemmer, “Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological
modeling,” Am. J. Physiol. Renal Physiol., vol. 321, no. 4, pp. F548–F557, Oct. 2021, doi: 10.1152/AJPRENAL.00233.2021.
41 Delanaye P, Wissing KM, Scheen AJ. Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. Clin Kidney J. 2021
Jun 11;14(12):2463-2471. doi: 10.1093/ckj/sfab096. PMID: 34950459; PMCID: PMC8690058.
42 Bailey CJ, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr Diab Rep. 2022 Jan;22(1):39-52.
doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3. PMID: 35113333; PMCID: PMC8888485.
43 Piperidou A, Loutradis C, Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021
Jan;35(1):12-25. doi: 10.1038/s41371-020-00393-4. Epub 2020 Aug 10. PMID: 32778748.
44 Joshi S, McMacken M, Kalantar-Zadeh K. Plant-Based Diets for Kidney Disease: A Guide for Clinicians. Am J Kidney Dis. 2021 Feb;77(2):287-296. doi:
10.1053/j.ajkd.2020.10.003. Epub 2020 Oct 16. PMID: 33075387.
45 Shabaka A, Cases-Corona C, Fernandez-Juarez G. Therapeutic Insights in Chronic Kidney Disease Progression. Front Med (Lausanne). 2021 Feb
23;8:645187. doi: 10.3389/fmed.2021.645187. PMID: 33708784; PMCID: PMC7940523.
46 Martínez-Montoro JI, Morales E, Cornejo-Pareja I, Tinahones FJ, Fernández- García JC. Obesity-related glomerulopathy: Current approaches and future perspectives. Obes Rev. 2022 Jul;23(7):e13450. doi: 10.1111/obr.13450. Epub 2022 Apr 1. PMID: 35362662; PMCID: PMC9286698.
47 L. Fried et al., “High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database,”
Nephrol. Dial. Transplant, Apr. 2022, doi: 10.1093/NDT/GFAC140.
A. J. Hahr and M. E. Molitch, “Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022,” Am. J. Kidney Dis., vol. 79, no. 5, pp. 728–
736, May 2022, doi: 10.1053/J.AJKD.2021.05.023.
48 Bailey CJ, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr Diab Rep. 2022 Jan;22(1):39-52.
doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3. PMID: 35113333; PMCID: PMC8888485.
49 S. Cohen, H. Sternlicht, and G. L. Bakris, “Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era
of SGLT2 Inhibitors and GLP-1 Receptor Agonists,” Curr. Diab. Rep., vol. 22, no. 5, pp. 213–218, May 2022, doi: 10.1007/S11892-022-01461-4.
50 T. Yamada et al., “Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and
chronic kidney disease: a systematic review and network meta-analysis,” Cardiovasc. Diabetol., vol. 20, no. 1, Dec. 2021, doi: 10.1186/S12933-020-01197-Z.
51 L. P. Gregg and S. D. Navaneethan, “Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?,” Nephrol. Dial. Transplant,
Oct. 2022, doi: 10.1093/NDT/GFAC284.
A. K. Singh and R. Singh, “Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the
past two decades!,” World J. Diabetes, vol. 13, no. 7, pp. 471–481, Jul. 2022, doi: 10.4239/WJD.V13.I7.471.
52 G. Filippatos et al., “Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis
of the FIDELIO-DKD trial,” Eur. J. Heart Fail., vol. 24, no. 6, pp. 996–1005, Jun. 2022, doi: 10.1002/EJHF.2469.
53 J. Barrera-Chimal, I. Lima-Posada, G. L. Bakris, and F. Jaisser, “Mineralocorticoid receptor antagonists in diabetic kidney disease – mechanistic and
therapeutic effects,” Nat. Rev. Nephrol., vol. 18, no. 1, pp. 56–70, Jan. 2022, doi: 10.1038/S41581-021-00490-8.
54 D. Türkmen et al., “Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients,” Br. J. Clin.
Pharmacol., 2022, doi: 10.1111/BCP.15541.
55 S. Y. Lin, C. L. Lin, C. C. Lin, W. H. Hsu, C. Y. Hsu, and C. H. Kao, “Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using
Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study,” Front. Pharmacol., vol. 13, Mar. 2022,
doi: 10.3389/FPHAR.2022.786203.
56 E. J. Morris, J. D. Brown, T. M. Manini, and S. M. Vouri, “Differences in Health-Related Quality of Life Among Adults with a Potential Dihydropyridine Calcium
Channel Blocker-Loop Diuretic Prescribing Cascade,” Drugs Aging, vol. 38, no. 7, pp. 625–632, Jul. 2021, doi: 10.1007/S40266-021-00868-0.
A. Benigni, S. Buelli, and D. E. Kohan, “Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value
to anti-renin-angiotensin system inhibition,” Pediatr. Nephrol., vol. 36, no. 4, pp. 763–775, Apr. 2021, doi: 10.1007/S00467-020-04518-2.
B. Taylor, M. Kasztan, B. Tao, J. S. Pollock, and D. M. Pollock, “Combined hydroxyurea and ETA receptor blockade reduces renal injury in the humanized sickle
cell mouse,” Acta Physiol. (Oxf)., vol. 225, no. 2, Feb. 2019, doi: 10.1111/APHA.13178.
57 R. Lariviere et al., “Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease,” J. Hypertens.,
vol. 35, no. 2, pp. 376–384, 2017, doi: 10.1097/HJH.0000000000001161.
58 S. Çalişkan, M. Sungur, B. Eser, M. Kanbay, H. Kocan, and R. Topaktas, “Endothelin-1 Level in Patients with Simple Renal Cyst,” Folia Med. (Plovdiv)., vol.
61, no. 4, pp. 545–550, Dec. 2019, doi: 10.3897/FOLMED.61.E47954.
59 J. H. Fang et al., “The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment,” Sci. Rep., vol. 11, no. 1, Dec. 2021,
doi: 10.1038/S41598-021-92753-4.
60 D. J. Leehey et al., “Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial,” BMJ Open, vol. 11, no. 8,
Aug. 2021, doi: 10.1136/BMJOPEN-2021-053019.
A. G. Casanova, F. J. López-Hernández, L. Vicente-Vicente, and A. I. Morales, “Are Antioxidants Useful in Preventing the Progression of Chronic Kidney
Disease?,” Antioxidants (Basel, Switzerland), vol. 10, no. 11, Nov. 2021, doi: 10.3390/ANTIOX10111669.
61 D. J. Leehey, “Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?,” Kidney360, vol. 1, no. 4, pp. 292–299, Apr. 2020,
doi: 10.34067/KID.0001252019.
62 Quintela BCSF, Carioca AAF, de Oliveira JGR, Fraser SDS, da Silva Junior GB. Dietary patterns and chronic kidney disease outcomes: A systematic review.
Nephrology (Carlton). 2021 Jul;26(7):603-612. doi: 10.1111/nep.13883. Epub 2021 Apr 28. PMID: 33864650.
63 W. W. Gao et al., “Locally transplanted human urine-induced nephron progenitor cells contribute to renal repair in mice kidney with diabetic nephropathy,”
Biochem. Biophys. Res. Commun., vol. 629, pp. 128–134, Nov. 2022, doi: 10.1016/J.BBRC.2022.09.015.
64 Y. Lu, L. Wang, M. Zhang, and Z. Chen, “Mesenchymal Stem Cell-Derived Small Extracellular Vesicles: A Novel Approach for Kidney Disease Treatment,”
Int. J. Nanomedicine, vol. 17, pp. 3603–3618, 2022, doi: 10.2147/IJN.S372254.
65 H. M. F. El Miniawy et al., “The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model,”
Stem Cell Res. Ther., vol. 13, no. 1, Dec. 2022, doi: 10.1186/S13287-022-03076-8.
66 S. Shrestha et al., “Role of HRTPT in kidney proximal epithelial cell regeneration: Integrative differential expression and pathway analyses using microarray
and scRNA-seq,” J. Cell. Mol. Med., vol. 25, no. 22, pp. 10466–10479, Nov. 2021, doi: 10.1111/JCMM.16976.
67 M. Assanatham et al., “Economic evaluation of peritoneal dialysis and hemodialysis in Thai population with End-stage Kidney Disease,” BMC Health Serv.
Res., vol. 22, no. 1, p. 1384, Nov. 2022, doi: 10.1186/S12913-022-08827-0.
68 P. I. Georgianos and R. Agarwal, “Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda,”
Curr. Hypertens. Rep., vol. 22, no. 10, Oct. 2020, doi: 10.1007/S11906-020-01081-X.
69 Z. Zhuang, M. Tong, R. Clarke, B. Wang, T. Huang, and L. Li, “Probability of chronic kidney disease and associated risk factors in Chinese adults: a crosssectional study of 9 million Chinese adults in the Meinian Onehealth screening survey,” Clin. Kidney J., vol. 15, no. 12, Nov. 2022, doi: 10.1093/CKJ/SFAC176.
70 R. Shulman and J. B. Cohen, “Resistant Hypertension in Chronic Kidney Disease: A Burden unto Itself,” Clin. J. Am. Soc. Nephrol., vol. 17, no. 10, pp.
1436–1438, Oct. 2022, doi: 10.2215/CJN.09720822.
